503 related articles for article (PubMed ID: 34220791)
21. A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
Zhang M; Cheng Y; Xue Z; Sun Q; Zhang J
BMC Cancer; 2021 Dec; 21(1):1311. PubMed ID: 34876094
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of a risk signature based on extracellular matrix-related genes in gliomas.
Liu J; Li G
Medicine (Baltimore); 2021 Apr; 100(16):e25603. PubMed ID: 33879726
[TBL] [Abstract][Full Text] [Related]
23. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
24. The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment.
Ning W; Qiu Z; Ji X; Wang X; An Y; Wang S; Zhang H
J Mol Neurosci; 2020 Oct; 70(10):1501-1511. PubMed ID: 32495005
[TBL] [Abstract][Full Text] [Related]
25. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
26. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
27. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
28. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
Zhang X; Sun X; Guo C; Li J; Liang G
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
[TBL] [Abstract][Full Text] [Related]
29. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
30. A robust two-gene signature for glioblastoma survival prediction.
Pan Y; Zhang JH; Zhao L; Guo JC; Wang S; Zhao Y; Tao S; Wang H; Zhu YB
J Cell Biochem; 2020 Jul; 121(7):3593-3605. PubMed ID: 31960992
[TBL] [Abstract][Full Text] [Related]
31. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
32. In silico analysis of the immune microenvironment in bladder cancer.
Zhang Y; Ou DH; Zhuang DW; Zheng ZF; Lin ME
BMC Cancer; 2020 Mar; 20(1):265. PubMed ID: 32228629
[TBL] [Abstract][Full Text] [Related]
33. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
34. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
35. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
36. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
37. A pyroptosis-related signature predicts prognosis and indicates immune microenvironment infiltration in glioma.
Chen J; Chen S; Li B; Zhou S; Lin H
Cancer Med; 2023 Feb; 12(4):5071-5087. PubMed ID: 36161280
[TBL] [Abstract][Full Text] [Related]
38. RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma.
Jin X; Xie H; Liu X; Shen Q; Wang Z; Hao H; Gu Y
Int Immunopharmacol; 2020 Oct; 87():106707. PubMed ID: 32683297
[TBL] [Abstract][Full Text] [Related]
39. Identification of INSRR as an immune-related gene in the tumor microenvironment of glioblastoma by integrated bioinformatics analysis.
Zhang H; Bao M; Liao D; Zhang Z; Tian Z; Yang E; Luo P; Jiang X
Med Oncol; 2023 Apr; 40(6):161. PubMed ID: 37099121
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatic Profiling Identifies a Glucose-Related Risk Signature for the Malignancy of Glioma and the Survival of Patients.
Zhao S; Cai J; Li J; Bao G; Li D; Li Y; Zhai X; Jiang C; Fan L
Mol Neurobiol; 2017 Dec; 54(10):8203-8210. PubMed ID: 27900679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
